The Financial Post reports in its Tuesday, Oct. 20, edition that Kimberly-Clark is selling investment-grade bonds to help fund its pending acquisition of Tylenol maker Kenvue. A Bloomberg dispatch to the Post reports that Kimberly-Clark is offering notes in as many as five parts with maturities of two to 10 years. Initial price discussions involve a premium of about one percentage point above U.S. Treasuries. Numerous companies held off on bringing high-grade bond sales last week as Treasury yields swung sharply on stronger-than-expected U.S. inflation data and worries about artificial intelligence trade. Kimberly-Clark's third quarter financial report is due on Nov. 5. Companies typically don't issue bonds in the roughly two-week period before disclosing results. JPMorgan provided $7.7-billion (U.S.) in bridge financing late last year to help fund the acquisition. The bond sale is expected to replace that temporary borrowing facility. Other banks managing the bond sale are Citigroup and Morgan Stanley. The largely-stock acquisition, expected to close by the end of the year, is currently valued at about $36-billion(U.S.).